Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALBINO: Allopurinol for Neonatal HIE
NCT03162653Phase 3Recruiting
- Sponsor
- University Hospital Tübingen
- Start
- Mar 2018
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in hypoxic-ischemic encephalopathy (HIE) comparing Allopurinol with Placebo (2 arms). Primary endpoint: Death versus severe neurodevelopmental impairment versus survival without severe neurodevelopmental impairment at 24 months. Started Mar 2018; status: recruiting.
02
Drugs
allopurinol
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on NCT03162653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03162653.